273 related articles for article (PubMed ID: 34465781)
1. A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity.
Das K; Belnoue E; Rossi M; Hofer T; Danklmaier S; Nolden T; Schreiber LM; Angerer K; Kimpel J; Hoegler S; Spiesschaert B; Kenner L; von Laer D; Elbers K; Derouazi M; Wollmann G
Nat Commun; 2021 Aug; 12(1):5195. PubMed ID: 34465781
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D
Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination.
Roy DG; Geoffroy K; Marguerie M; Khan ST; Martin NT; Kmiecik J; Bobbala D; Aitken AS; de Souza CT; Stephenson KB; Lichty BD; Auer RC; Stojdl DF; Bell JC; Bourgeois-Daigneault MC
Nat Commun; 2021 May; 12(1):2626. PubMed ID: 33976179
[TBL] [Abstract][Full Text] [Related]
4. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG
Hum Gene Ther; 2010 Apr; 21(4):439-50. PubMed ID: 19922169
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer.
McGray AJR; Huang RY; Battaglia S; Eppolito C; Miliotto A; Stephenson KB; Lugade AA; Webster G; Lichty BD; Seshadri M; Kozbor D; Odunsi K
J Immunother Cancer; 2019 Jul; 7(1):189. PubMed ID: 31315674
[TBL] [Abstract][Full Text] [Related]
6. Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis.
Ben Yebdri F; Van Grevenynghe J; Tang VA; Goulet ML; Wu JH; Stojdl DF; Hiscott J; Lin R
Mol Ther; 2013 Nov; 21(11):2043-53. PubMed ID: 23985699
[TBL] [Abstract][Full Text] [Related]
7. Detection of Tumor Antigen-Specific T-Cell Responses After Oncolytic Vaccination.
Pol JG; Bridle BW; Lichty BD
Methods Mol Biol; 2020; 2058():191-211. PubMed ID: 31486039
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy.
Kottke T; Tonne J; Evgin L; Driscoll CB; van Vloten J; Jennings VA; Huff AL; Zell B; Thompson JM; Wongthida P; Pulido J; Schuelke MR; Samson A; Selby P; Ilett E; McNiven M; Roberts LR; Borad MJ; Pandha H; Harrington K; Melcher A; Vile RG
Nat Commun; 2021 Mar; 12(1):1930. PubMed ID: 33772027
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.
Durham NM; Mulgrew K; McGlinchey K; Monks NR; Ji H; Herbst R; Suzich J; Hammond SA; Kelly EJ
Mol Ther; 2017 Aug; 25(8):1917-1932. PubMed ID: 28578991
[TBL] [Abstract][Full Text] [Related]
10. Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus.
Wongthida P; Diaz RM; Pulido C; Rommelfanger D; Galivo F; Kaluza K; Kottke T; Thompson J; Melcher A; Vile R
Hum Gene Ther; 2011 Nov; 22(11):1343-53. PubMed ID: 21366404
[TBL] [Abstract][Full Text] [Related]
11. Combination of virotherapy with VSV and tumor vaccination significantly enhances the efficacy of antitumor therapy.
Sobhanimonfared F; Bamdad T; Sadigh ZA; Nikoo HR; Choobin H
Acta Virol; 2018; 62(4):394-400. PubMed ID: 30472869
[TBL] [Abstract][Full Text] [Related]
12. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.
Willmon C; Diaz RM; Wongthida P; Galivo F; Kottke T; Thompson J; Albelda S; Harrington K; Melcher A; Vile R
Mol Ther; 2011 Jan; 19(1):140-9. PubMed ID: 20978474
[TBL] [Abstract][Full Text] [Related]
13. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
[TBL] [Abstract][Full Text] [Related]
14. Xenoantigen-Dependent Complement-Mediated Neutralization of Lymphocytic Choriomeningitis Virus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus in Human Serum.
Pipperger L; Koske I; Wild N; Müllauer B; Krenn D; Stoiber H; Wollmann G; Kimpel J; von Laer D; Bánki Z
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243134
[TBL] [Abstract][Full Text] [Related]
15. Vesicular stomatitis virus sensitizes immunologically cold tumors to checkpoint blockade by inducing pyroptosis.
Lin J; Liu F; Gao F; Chen Y; Wang R; Wang X; Li Y; Li Q; Sun S; Li Z; Lan Y; Lu H; Guo W; Du L; Gao F; Song D; Zhao K; Guan J; He W
Biochim Biophys Acta Mol Basis Dis; 2022 Dec; 1868(12):166538. PubMed ID: 36096276
[TBL] [Abstract][Full Text] [Related]
16. The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma.
Kimpel J; Urbiola C; Koske I; Tober R; Banki Z; Wollmann G; von Laer D
Viruses; 2018 Mar; 10(3):. PubMed ID: 29498639
[TBL] [Abstract][Full Text] [Related]
17. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
[TBL] [Abstract][Full Text] [Related]
18. Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer.
Nelson A; McMullen N; Gebremeskel S; De Antueno R; Mackenzie D; Duncan R; Johnston B
Breast Cancer Res; 2024 May; 26(1):78. PubMed ID: 38750591
[TBL] [Abstract][Full Text] [Related]
19. Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.
Lemay CG; Rintoul JL; Kus A; Paterson JM; Garcia V; Falls TJ; Ferreira L; Bridle BW; Conrad DP; Tang VA; Diallo JS; Arulanandam R; Le Boeuf F; Garson K; Vanderhyden BC; Stojdl DF; Lichty BD; Atkins HL; Parato KA; Bell JC; Auer RC
Mol Ther; 2012 Sep; 20(9):1791-9. PubMed ID: 22760544
[TBL] [Abstract][Full Text] [Related]
20. Prediction and validation of murine MHC class I epitopes of the recombinant virus VSV-GP.
Vijver SV; Danklmaier S; Pipperger L; Gronauer R; Floriani G; Hackl H; Das K; Wollmann G
Front Immunol; 2022; 13():1100730. PubMed ID: 36741416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
